PhRMA Defends 30-Month ANDA Stay In McCain/Schumer Position Paper
This article was originally published in The Tan Sheet
Executive Summary
The brand vs. generic industry positioning surrounding proposed Hatch/Waxman process reforms includes conflicting arguments over the potential for standard intellectual property procedures to protect pharmaceutical companies from patent infringement.
You may also be interested in...
Antihistamines OTC Switch Battle Moves To Capitol Hill
A House subcommittee will examine FDA's legal authority to initiate an Rx-to-OTC switch without the sponsor's consent during a June 13 hearing.
McCain/Schumer Generic Drug Bill Would End 30-Month Stay Of Approval
The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC